The Ratio of ADP- to TRAP-Induced Platelet Aggregation Quantifies P2Y(12)-Dependent Platelet Inhibition Independently of the Platelet Count by Olivier, Christoph B. et al.
RESEARCH ARTICLE
The Ratio of ADP- to TRAP-Induced Platelet
Aggregation Quantifies P2Y12-Dependent
Platelet Inhibition Independently of the
Platelet Count
Christoph B. Olivier1*, Melanie Meyer1, Hans Bauer2, Katharina Schnabel1, Patrick Weik1,
Qian Zhou1, Christoph Bode1, Martin Moser1, Philipp Diehl1
1 Heart Center Freiburg University, Cardiology and Angiology I, Freiburg—Bad Krozingen, Germany,





This study aimed to assess the association of clinical factors with P2Y12-dependent platelet
inhibition as monitored by the ratio of ADP- to TRAP-induced platelet aggregation and con-
ventional ADP-induced aggregation, respectively.
Background
Controversial findings to identify and overcome high platelet reactivity (HPR) after coronary
stent-implantation and to improve clinical outcome by tailored anti-platelet therapy exist.
Monitoring anti-platelet therapy ex vivo underlies several confounding parameters causing
that ex vivo platelet aggregation might not reflect in vivo platelet inhibition.
Methods
In a single centre observational study, multiple electrode aggregometry was performed in
whole blood of patients after recent coronary stent-implantation. Relative ADP-induced
aggregation (r-ADP-agg) was defined as the ratio of ADP- to TRAP- induced aggregation
reflecting the individual degree of P2Y12-mediated platelet reactivity.
Results
Platelet aggregation was assessed in 359 patients. Means (± SD) of TRAP-, ADP-induced
aggregation and r-ADP-agg were 794 ± 239 AU*min, 297 ± 153 AU*min and 37 ± 14%,
respectively. While ADP- and TRAP-induced platelet aggregation correlated significantly
with platelet count (ADP: r = 0.302; p<0.001; TRAP: r = 0.509 p<0.001), r-ADP-agg values
did not (r = -0.003; p = 0.960). These findings were unaltered in multivariate analyses
adjusting for a range of factors potentially influencing platelet aggregation. The presence of
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an acute coronary syndrome and body weight were found to correlate with both ADP-
induced platelet aggregation and r-ADP-agg.
Conclusion
The ratio of ADP- to TRAP-induced platelet aggregation quantifies P2Y12-dependent plate-
let inhibition independently of the platelet count in contrast to conventional ADP-induced
aggregation. Furthermore, r-ADP-agg was associated with the presence of an acute coro-
nary syndrome and body weight as well as ADP-induced aggregation. Thus, the r-ADP-agg
is a more valid reflecting platelet aggregation and potentially prognosis after coronary stent-
implantation in P2Y12-mediated HPR than conventional ADP-induced platelet aggregation.
Introduction
After coronary stent-implantation, guidelines recommend a dual anti-platelet therapy with
ASA and P2Y12-receptor antagonists. Clopidogrel is the most widely used P2Y12-antagonist.
Clinical trials have demonstrated that high platelet reactivity (HPR) after clopidogrel adminis-
tration increases the risk of recurrent atherothrombotic events [1]. However, controversial
findings to identify and overcome HPR after coronary stent-implantation and to improve clini-
cal outcome by tailored anti-platelet therapy exist [2–8]. Patients with HPR are commonly
identified by ADP-induced platelet aggregometry, performed by VerifyNow1 assay and multi-
ple electrode aggregometry (MEA) [9]. However, ex vivo platelet aggregation is potentially
influenced by biasing factors (e.g. parameters of the haemogram) making it hard to transfer
results from platelet aggregometry on in vivo platelet function [10]. It has been suggested that
activating platelets via Thrombin Receptor Activating Peptide (TRAP) and the thrombin recep-
tor might serve as an “internal control” for ADP-induced platelet inhibition [11, 12], to selec-
tively indicate the degree of P2Y12–mediated platelet reactivity.
Recently, our group showed that the ratio of ADP- to TRAP-induced platelet aggregation
(r- ADP-agg) is a valuable tool reflecting a patient’s individual degree of P2Y12–mediated plate-
let reactivity and that a high r-ADP-agg is associated with an increased mortality in patients
after coronary stent-implantation on clopidogrel [13, 14]. This data suggest that r-ADP-agg
might predict the clinical outcome of patients after percutaneous coronary intervention more
precisely than ADP-induced platelet aggregation alone.
The aim of the present study was to further investigate the clinical utility of r-ADP-agg by
analysing clinical factors influencing P2Y12-dependent platelet reactivity as monitored by r-
ADP-agg in comparison to conventional ADP-induced aggregation.
Methods
Study design and clinical characteristics
Data of this study were collected during an observational single centre study in which the anti-
platelet effect of clopidogrel in patients after coronary stent implantation had been investigated.
The study was performed in accordance with the Helsinki declaration and was approved by the
ethics committee of the Albert-Ludwigs-University Freiburg, Germany (registry number 183/
07). All patients gave their written informed consent prior to study participation. Patients were
included prospectively in the Department of Cardiology and Angiology at the Heart Center of
the University of Freiburg from 2007 to 2011. All patients received 100 mg ASA per day and 75
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mg clopidogrel after a loading dose of 300 mg (at least 24 hours before platelet aggregation
assay) or 600 mg (at least 12 hours before platelet aggregation assay). The washout period for
the GPIIb/IIIa antagonist eptifibatid was 12 hours. Patients with coagulation disorders such as
antiphospholipid syndrome were excluded.
Blood samples
Venous blood was collected using a 21 G butterfly needle (Safety-Multifly1-Set, Sarstedt,
Nümbrecht, Germany) to a final concentration (Fc) of>15 μg/ml r-hirudin (SARSTEDT
Monovetten, Nümbrecht, Germany). To prevent storage induced platelet activation, blood
samples were analysed within the first two hours after venous puncture.
Platelet aggregometry
Multiple electrode aggregometry (MEA, Roche Diagnostics, Switzerland) was performed in
whole blood of patients after percutaneous coronary intervention (PCI) under anti-platelet
medication as recently described [13, 14]. In order to assess the overall platelet aggregability,
blood samples were stimulated with TRAP (Fc 32 μM). To specifically quantify the effect of
P2Y12-inhibitors, whole blood was stimulated with ADP (Fc 6.4 μM). R-ADP-agg was defined
as the ratio of ADP- to TRAP-induced platelet aggregation.
Statistical analysis
Data are presented as numbers with frequencies for categorical variables and means with stan-
dard deviations (SD) for continuous variables. The Kolmogorov-Smirnov test was applied to
assess normality. Group comparisons for normally distributed variables were performed with
Student's t-test. In non-normally distributed parameters, the Mann-Whitney U test was used.
Correspondingly, Pearson’s or Spearman’s coefficients were used for bivariate correlational
analyses. All tests were 2-tailed and p values0.05 were considered statistically significant.
The association of covariates was tested by analyses of covariance (ANCOVA). To identify
patient characteristics that show a significant association with aggregation markers even after
mutual statistical adjustment (accounting for confounding effects), separate multiple regres-
sion models of the three aggregation markers including potentially relevant influencing avail-
able factors (following the review of Siller-Matula et al. [15]) as covariates were run on all
patients with complete data. The final models reported here were then obtained by a backward
elimination procedure removing all covariates with a p value>0.1 in a stepwise manner. Data
were analysed with Prism 5.01 (GraphPad Software, La Jolla, California, USA) and SPSS
21.0.0.1 (SPSS Inc, Chicago, Illinois, USA).
Results
Sample characteristics
In total, platelet function was assessed in 359 patients. The mean of TRAP-induced aggrega-
tion, ADP-induced aggregation and r-ADP-agg was 794 ± 239 AUmin, 297 ± 153 AUmin
and 37 ± 14% respectively. ADP- and TRAP-induced aggregation correlated significantly
(r = 0.623, p<0.001), while r-ADP-agg correlated significantly with ADP-induced aggregation
(r = 0.769, p<0.001) but not with TRAP-induced aggregation (r = 0.041, p = 0.041). Clinical
baseline characteristics are shown in Table 1.
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Aggregation Markers
While ADP- and TRAP-induced platelet aggregation correlated significantly with platelet
counts (PC) (ADP: r = 0.302, p<0.001; TRAP: r = 0.509, p<0.001), the r-ADP-agg values were
independent of those (r = -0.003; p = 0.960) (Fig 1). A significant correlation of white blood
cell counts (WBC) with ADP- and TRAP-induced aggregation (ADP: r = 0.229, p<0.001;
Table 1. Clinical baseline characteristics.
n = 359
Age [years] 70 (12)
Male sex 245 (68)
Body weight [kg] 79 (16)
Procedural data
Acute Coronary Syndrome 210 (58)
One-vessel CAD 72 (20)
Two-vessel CAD 86 (24)
Three-vessel CAD 201 (56)
Implanted stents 1.3 (0.7)
Medical history
Previous MI 77 (21)
Severely reduced LV-function 31 (8.6)
Implanted cardioverter-defibrillator 15 (4.2)
Atrial fibrillation 65 (18)
Stroke/transient ischemic attack 40 (11)
Gastrointestinal bleeding 10 (2.8)
Cardiovascular risk factors
History of smoking 148 (41)
Diabetes mellitus 106 (30)
Arterial hypertension 275 (77)
Family history of MI 85 (24)
Hyperlipidemia 213 (59)
Laboratory data
WBC [103/μl] 8.2 (2.8)
RBC [103/μl] 4.5 (0.6)
Platelets [103/μl] 230 (71)
Haemoglobin [g/dl] 13 (1.9)
CK [U/ml] 280 (710)
CRP [mg/l] 15 (26)
Cholesterol [mg/dl] 190 (43)
Creatinine [mg/dl] 1.1 (0.6)
Comedication
ACE inhibitor 245 (68)
β blocker 312 (87)
Calcium antagonist 88 (25)
Diuretic 148 (41)
Statin 319 (89)
Proton-pump inhibitor 196 (55)
Oral anticoagulant 17 (4)
Data are n (%) or mean (SD).
doi:10.1371/journal.pone.0149053.t001
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TRAP: r = 0.278, p<0.001) was observed while this was not found for r-ADP-agg (r = 0.083;
p = 0.118). No significant correlation was found for all aggregation markers with red blood cell
counts (RBC) (ADP: r = 0.021, p = 0.689; TRAP: r = -0.071, p = 0.183; r-ADP-agg: r = 0.071;
p = 0.181). Furthermore, factors that might influence platelet reactivity after clopidogrel treat-
ment were analysed following the description of Siller-Matula [15, 16] according to availability
as shown in Table 2. Body weight was found to correlate significantly with both ADP-induced
platelet aggregation (r = 0.143, p = 0.007) and r-ADP-agg (r = 0.157, p = 0.003), but not with
TRAP-induced platelet aggregation. Nevertheless, it was found that TRAP-induced platelet
Fig 1. While ADP- and TRAP-induced platelet aggregation correlated significantly with platelet counts the r-ADP-agg values were independent of
those.
doi:10.1371/journal.pone.0149053.g001






Continuous variables correlation p-value correlation p-value correlation p-value
WBC [103/μl] 0.229 <0.001 0.278 <0.001 0.083 0.118
RBC [103/μl] 0.021 0.689 -0.071 0.183 0.071 0.181
Age [years] -0.098 0.066 -0.105 0.048 -0.016 0.762
Body weight [kg] 0.143 0.007 -0.020 0.704 0.157 0.003
CRP [mg/dl] 0.099 0.123 0.056 0.379 0.086 0.178
Cholesterol [mg/dl] -0.106 0.229 -0.023 0.795 -0.063 0.475
Creatinine [mg/dl] 0.026 0.629 0.026 0.621 0.016 0.762
Categorical variables mean (SD) p-value mean (SD) p-value mean (SD) p-value
male vs. 305 (152) vs. 0.110 788 (239) vs. 0.313 39 (14) vs. 0.032
Female 288 (165) 815 (246) 35 (14)
ACS vs. 323 (159) vs. <0.001 801 (243) vs. 0.888 40 (13) vs. <0.001
No ACS 266 (146) 790 (239) 34 (14)
Severely reduced LV-function vs. 286 (146) vs. 0.757 776 (237) vs. 0.798 37 (15) vs. 0.812
Not severely reduced LV function 300 (158) 799 (242) 37 (14)
Diabetes mellitus vs. 327 (183) vs. 0.120 835 (252) vs. 0.052 39 (15) vs. 0.301
no diabetes mellitus 287 (143) 781 (235) 37 (14)
β-blocker vs. 305 (156) vs. 0.041 799 (237) vs. 0.757 38 (14) vs. 0.022
No β-blocker 264 (156) 183 (267) 33 (15)
Calcium antagonist vs. 291 (171) vs. 0.324 797 (260) vs. 0.947 36 (14) vs. 0.229
No calcium antagonist 302 (152) 797 (235) 38 (14)
PPI vs. 315 (169) vs. 0.062 821 (255) vs. 0.073 38 (15) vs. 0.437
No PPI 277 (136) 767 (220) 36 (13)
doi:10.1371/journal.pone.0149053.t002
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aggregation correlated significantly with age (r = -0.105, p = 0.048) while this was not seen for
ADP-induced aggregation or r-ADP-agg. Creatinine levels did not correlate significantly with
any of the aggregation markers. Although CRP and cholesterol was not available in all patients
(n = 245 and 129 respectively) no significant correlations were found.
In the analysis of categorical variables there was a trend towards a higher r-ADP-agg in
male compared to female patients (p = 0.032). This observation is most likely explained by a
higher body weight in men compared to women (mean male vs. female: 84 ± 14 vs 69 ± 15 kg;
p<0.001). Consistent with this explanation, analysis of covariance (ANCOVA) showed that
the difference between the hypothetical means adjusted for the covariate body weight was sub-
stantially smaller (hypothetical means for r-ADP-agg; male: 38% vs female 36%; p = 0.317).
Furthermore, ADP-induced aggregation and r-ADP-agg were enhanced in patients presenting
with an acute coronary syndrome (ACS) (effect size for ADP: r = 0.364, p<0.001; r-ADP-agg:
r = 0.423, p<0.001) and under treatment with β-blockers (effect size for ADP: r = 0.262,
p = 0.041; r-ADP-agg: r = 0.352, p = 0.022). Severely reduced left ventricular function, diabetes
mellitus, the use of calcium antagonists or proton pump inhibitors were not associated signifi-
cantly with aggregation markers.
Results of the multiple regression analyses to identify factors significantly associated with
aggregations markers under mutual adjustment are presented in Table 3. Only parameters of
covariates that were retained in the model of the respective aggregation marker during the
backward elimination procedure are included in the table. Cholesterol and CRP were not
included in the multiple regression analyses because these biomarkers were not available in all
Table 3. Factors significantly associated with aggregationmarkers in multiple regression analyses (all N = 351).
ADP induced aggregation [AU*min] TRAP-induced aggregation [AU*min] r-ADP-agg [%]
Coef 95% CI Std
Coef
p Coef 95% CI Std
Coef





- - 470.92 333.04;
608.81
- - 19.67 11.69;
27.66
- -
Platelets [103/μl] 0.82 0.61; 1.04 0.37 <0.001 1.89 1.60; 2.19 0.55 <0.001 - - - -
WBC [103/μl] - - - - - - - - - - - -
RBC [103/μl] - - - - - - - - - - - -
Age [years] - - - - -1.78 -3.47; -0.10 -0.09 0.038 - - - -
Body weight [kg] 1.40 0.45; 2.34 0.14 0.004 - - - - 0.14 0.05; 0.23 0.15 0.003
Creatinine [mg/dl] - - - - - - - - - - - -





0.14 0.006 - - - - 5.90 2.99; 8.81 0.21 <0.001
Severely reduced LV
func.
- - - - - - - - - - - -
Diabetes mellitus 37.14 4.55; 69.72 0.11 0.026 52.47 6.42; 98.51 0.10 0.026 - - - -
β-blocker 49.35 4.81; 93.89 0.11 0.030 - - - - 4.05 -0.25; 8.36 0.10 0.065
Calcium antagonist - - - - - - - - - - - -
Proton pump inhibitor 27.20 -3.24; 57.63 0.09 0.080 - - - - - - - -
R2 0.206 0.325 0.084
Coef: Regression coefficient. CI: Confidence interval. Std coef: Standardized regression coefficient. Variables where no units are provided in brackets are
binary. Models were run seperately with each of the three aggregation markers as the outcome, initially including all factors displayed in this table as
covariates, and then removing covariates with p > 0.1 in a backward elimination procedure. Covariates where the coefficient is missing were removed
from the respective model in this manner.
doi:10.1371/journal.pone.0149053.t003
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patients. Furthermore, their bivariate correlations with aggregation markers were quite weak
(all |r|< 0.11).
With regards to ADP-induced aggregation, there was no significant association between
WBC and ADP-induced aggregation in the multiple regression models, in contrast to the bivari-
ate correlation coefficient reported above. This pattern of results can be explained by a confound-
ing effect of platelet count, as also evidenced by a significant bivariate correlation between PC
andWBC (r = 0.315; p<0.001). In contrast, PC is retained in the model. In fact, it has the stron-
gest association with ADP-induced aggregation among all patient characteristics, as evidenced by
the standardized coefficient. Further relevant factors include body weight, the presence of ACS or
diabetes, use of beta blockers and, to a lesser degree, of proton pump inhibitors.
Like ADP-induced aggregation, TRAP-induced aggregation is significantly predicted by
diabetes and platelet count. Age is uniquely associated with TRAP, whereas other factors rele-
vant in ADP-induced aggregation do not play a noticeable role. Thus, TRAP is associated with
fewer characteristics than ADP-induced aggregation, however, the association with PC is so
strong that the percentage of explained variation is 32.5%, as opposed to 20.6 in ADP-induced
aggregation.
Finally, r-ADP-agg is significantly predicted by body weight, the presence of ACS, and the
use of beta blockers. There is no significant difference between the sexes after adjustment for
the other covariates, consistent with the results of the corresponding ANCOVA adjusting for
body weight. Most importantly, r-ADP-agg is the only one of the aggregation markers not
associated with platelet count, confirming the corresponding bivariate analyses. Of note, the
strongest association of r-ADP-agg is with ACS (as measured by standardized coefficients),
which highlights the potential clinical utility of this aggregation marker. The proportion of var-
iation in r-ADP-agg explained by the examined patient characteristics (8.4%) is noticeably
lower than that in the other markers.
Discussion
The principal finding of this study is that r-ADP-agg does not depend on platelet count while
conventional ADP-induced aggregation does.
Data published in 2011 by Gremmel et al. confirm our results: ADP-induced aggregation
measured by MEA depends on the PC [17]. Interestingly, they found that this was only the
case for MEA and not for other methods. The reason for this finding might be related to the
underlying mechanism of MEA: activated by an agonist, the platelets adhere to the electrodes
and cause the change of impedance. Higher platelet numbers might therefore cause higher
changes of impedance [17].
Voisin et al. assessed platelet aggregation in 186 patients under dual anti-platelet therapy
using VerifyNow [10]. They showed that ADP- and TRAP-induced platelet aggregation signifi-
cantly decrease with increasing haematocrit or haemoglobin, whereas a ratio of ADP- to
TRAP-induced aggregation does not which might be due to a parallel change of both markers.
Nevertheless, they suggested that the ADP- to TRAP-induced ratio more precisely reflects
P2Y12-mediated platelet aggregation and hence can be used to assess the effect of P2Y12-recep-
tor inhibition. In the study of Voisin et al. data of platelet and white blood cell count and the
influence on aggregation markers is not shown. Although, in the present study using MEA
there was no association of the red blood cell count with aggregation markers, the findings of
Voisin et al. confirm that platelet aggregometry might not be independent of haematological
variables. Nevertheless, in contrast to the VerifyNow1 assay it has been suggested that r-ADP-
agg measured by MEA might be more precise to predict clinical outcome than conventional
ADP-induced aggregation alone [14].
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Numerous factors can influence the extent of platelet inhibition by clopidogrel [15, 16].
Some of these factors are assay-dependent [13], which is also partly evidenced by the present
study’s results. For example, presence of diabetes and proton pump inhibitor medication
appeared to be more strongly associated with ADP-induced aggregation than with r-ADP-
agg. Increased r-ADP-agg in men and the correlation of ADP-induced aggregation with
WBC may be explained in terms of confounding by body weight and platelet count,
respectively.
At the same time, however, the association between PC and r-ADP-agg remained very weak
and non-significant in both bivariate and multivariate analyses, whereas there was a clearly
detectable association between PC and ADP-induced aggregation which remained even after
adjusting for a range of other patient characteristics. As PC can be considered a nuisance factor
in the selective assessment of P2Y12-mediated platelet reactivity, r-ADP-agg may have higher
clinical utility than conventional ADP-induced aggregation in the diagnosis of P2Y12-mediated
HPR and associated thrombotic events. In the present analysis, approximately 10% of the vari-
ance in ADP-induced aggregation measurements could be explained by variations in patients’
PC (r2 = 0.3022 = 0.091) and could be considered nuisance variation leading to reduced preci-
sion in the quantification of individual P2Y12-mediated platelet reactivity. Eliminating this
source of variation, as in r-ADP-agg, may thus lead to higher precision and higher power to
detect the effects of prognostic and interventional factors on clinical outcomes. For example,
our group recently showed that a high r-ADP-agg is associated with an increased mortality in
patients after coronary stent-implantation and clopidogrel therapy [14]. Further clinical trials
should evaluate if an adaption of P2Y12-inhibition monitored by r-ADP-agg can improve clini-
cal outcome.
In the multiple regression model both, ADP-induced aggregation and r-ADP-agg were asso-
ciated with the presence of an ACS setting and body weight. These factors had been described
previously to be associated with HPR [15]. Interestingly, among all investigated patient charac-
teristics, r-ADP-agg was most strongly associated with the presence of ACS.
TRAP is one of the strongest platelet activators and leads to pronounced platelet aggregation
[18–20]. Badr et al. recently observed that platelet activation via thrombin receptors PAR-1
and PAR-4 is preserved in the majority of patients after platelet inhibition with clopidogrel.
Nevertheless, it has been described that TRAP-induced platelet aggregation is slightly reduced
in patients under treatment by thienopyridines [21]. However, Iyu et al. recently found that
P2Y12-antagonists produced only minor additional inhibition of TRAP-induced aggregation
and found no evidence that any of the P2Y12-antagonists act through other G-protein receptors
including PAR1 [22]. Results from our group comparing different P2Y12-inhibitors showed
that there are no differences of the TRAP-induced platelet aggregation in the corresponding
medication group [13]. Although controversial findings exist on the influence of P2Y12-inhibi-
tors TRAP-induced aggregation might be a reasonable internal control for patients under clo-
pidogrel medication, as also stated by Gremmel et al. in 2010 [11, 12]. Nevertheless, in patients
receiving co-medication that might influence TRAP-induced platelet aggregation such as vora-
paxar the r-ADP-agg might not be applicable to monitor HPR after clopidogrel treatment [19,
23, 24].
Study Limitations
The present study is based on a post-hoc analysis of observational data. Therefore, confounders
cannot be excluded. As we only performed a single measurement of platelet reactivity in the
steady state of clopidogrel intake, pharmacodynamic differences in the first hours are not dis-
played. Only one method of platelet aggregometry was performed.
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Conclusion
The ratio of ADP- to TRAP-induced platelet aggregation quantifies P2Y12-dependent platelet
inhibition independently of the PC in contrast to conventional ADP-induced aggregation. Fur-
thermore, r-ADP-agg was associated with the presence of an ACS and body weight as well as
ADP-induced aggregation. Thus, the r-ADP-agg is a more valid reflecting platelet aggregation
and potentially prognosis after coronary stent-implantation in P2Y12-mediated HPR than con-
ventional ADP-induced platelet aggregation. Whether an adaption of P2Y12-antagonism mon-
itored by r-ADP-agg can provide an additional clinical benefit needs to be evaluated in further
trials.
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